| Assessment Status | Rapid Review Complete |
| HTA ID | 26043 |
| Drug | Nivolumab and Ipilimumab |
| Brand | Opdivo® and Yervoy® |
| Indication | Nivolumab is indicated as monotherapy or in combination with ipilimumab for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older |
| Assessment Process | |
| Rapid review commissioned | 28/08/2026 |
| Rapid review completed | 30/09/2026 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that nivolumab as monotherapy or in combination with ipilimumab not be considered for reimbursement for this indication at the submitted price. |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here
Further information on the status of this decision may be found here